[Effect of celiprolol and metoprolol on serum lipids in patients with various forms of hyperlipoproteinemia].
In a single-blind prospective study, patients with hyperlipoproteinemias of the types II a, II b or IV were examined for changes of their serum lipid levels under the treatment with 300 mg celiprolol or 200 mg metoprolol, respectively, for a period of 4 weeks. Celiprolol led to a reduction of serum triglycerides, while the total cholesterol level remained practically unchanged; the HDL-cholesterol level rose from an average of 41.7 to 53.9 mg/dl (p less than or equal to 0.05). There was a slight increase of the LDL-cholesterol level and a significant decrease of the quotients between LDL- and HDL-cholesterol and between total cholesterol and HDL-cholesterol. Metoprolol caused a slight increase of the serum triglycerides, the total cholesterol level remained unchanged, while the HDL-cholesterol level slightly increased from 56.7 to 59.3 mg/dl. The level of LDL-cholesterol and the quotient between LDL-cholesterol and HDL-cholesterol decreased slightly. On the contrary, the quotient between total cholesterol and HDL-cholesterol remained practically unchanged. Celiprolol had a favourable influence on the serum lipid pattern, as far as the atherogenic risk is concerned.
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects*; D001794:Blood Pressure / Q000187:drug effects; D017272:Celiprolol; D002784:Cholesterol / Q000097:blood; D002986:Clinical Trials as Topic; D006801:Humans; D006951:Hyperlipoproteinemias / Q000097:blood*; D008055:Lipids / Q000097:blood*; D008074:Lipoproteins / Q000097:blood; D008790:Metoprolol / Q000009:adverse effects*; D008875:Middle Aged; D011412:Propanolamines / Q000009:adverse effects*; D012306:Risk; D014280:Triglycerides / Q000097:blood
D000319:Adrenergic beta-Antagonists; D008055:Lipids; D008074:Lipoproteins; D011412:Propanolamines; D014280:Triglycerides; D002784:Cholesterol; D017272:Celiprolol; D008790:Metoprolol
Wirkung von Celiprolol und Metoprolol auf die Serumlipide bei Patienten mit verschiedenen Formen von Hyperlipoproteinämie.